Current status, of the Arilvax™ yellow fever vaccine

Expert Review of Vaccines

Volumn 3, Issue 4, 2004, Pages 413-420

  Barrett, Alan D T ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

17D; Arilvax; Live attenuated vaccine; Yellow fever

Indexed keywords

LIVE VACCINE; YELLOW FEVER VACCINE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG SAFETY; ENCEPHALITIS; FEVER; HEADACHE; HEMORRHAGIC FEVER; HUMAN; IMMUNE RESPONSE; IMMUNITY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MULTIPLE ORGAN FAILURE; MYALGIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VACCINATION; YELLOW FEVER;

CLINICAL TRIALS, PHASE III; HUMANS; WORLD HEALTH ORGANIZATION; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 4043117698     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.4.413     Document Type: Review

References (30)

1. Robertson SE, Hull BP, Tomori O et al. Yellow fever: a decade of re-emergence. JAMA 276, 1157-1162 (1996). Describes the re-emergence of yellow fever and its consequences.
2. Barrett ADT, Monath TP. Epidemiology and ecology of yellow fever virus. In: Flaviviruses. Chambers T, Monath TP (Eds). Adv. Virus Res. 61, 291-315 (2003).
3. Monath TP, Barrett ADT. Pathogenesis and pathophysiology of yellow fever. In: Flaviviruses. Chambers T, Monath TP (Eds). Adv. Virus Res. 60, 343-395 (2003).
4. Barrett ADT. Yellow fever vaccines. Biologicals 25, 17-25 (1997).
5. Monath TP. Yellow fever. In: Vaccines. 3rd Edition. Plotkin SA, Orenstein WA (Eds). WB Saunders Inc. PA, USA, 815-869 (1999).
6. World Health Organization. Requirements for yellow fever vaccine. WHO Technical Report Series 872, 31-68 (1998). Describes the criteria for 17D vaccine and its manufacture.
7. Yellow fever vaccine. Wkly Epidemiol. Rec. 78, 349-359 (2003). The most recent review of the status of yellow fever disease and the 17D vaccine.
8. Pugachev KV, Ocran SW, Guirakhoo F, Furby D, Monath TP. Heterogeneous nature of the genome of the Arilvax yellow fever 17D vaccine revealed by consensus sequencing. Vaccine 20, 996-999 (2002).
9. Rice CM, Lenches EM, Eddy SR et al. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229, 726-733 (1985).
10. Marchevsky RS, Freire MS, Coufinho ES, Galler R. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. Virology 316, 55-63 (2003).
11. Roehrig JT. Antigenic structure of flavivirus proteins. Adv. Virus. Res. 59, 141-175 (2003).
12. Holbrook MR, Holbrook MR, Wang H, Barrett AD. Langat virus M protein is structurally homologous to prM. J. Virol. 75, 3999-4001 (2001).
13. Gibson CA, Schlesinger JJ, Barrett AD. Prospects for a virus nonstructural protein as a subunit vaccine. Vaccine 6, 7-9 (1988).
14. Co MD, Terajima M, Cruz J, Ennis FA, Rothman AL. Human cytotoxic T-lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 293, 151-163 (2002).
15. van der Most RG, Harrington LE, Giuggio V, Mahar PL, Ahmed R. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T-cell response in mice. Virology 296, 117-124 (2002).
16. Advisory Committee on Immunization Practices. Yellow fever vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 51, (RR17), 1-10 (2002). Reviews the recommendations of when to immunize against yellow fever and contraindications.
17. Vasconconcelos PFC, Luna EJ, Galler R et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358, 91-97 (2001).
18. Chan RC, Penney DJ, Little D et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 358, 121-122 (2001).
19. Martin M, Tsai TF, Cropp B et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358, 98-104 (2001).
20. Martin M, Ward LH, Tsai TF et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg. Inf. Dis. 7, 945-951 (2001).
21. Galler R, Pugachev KV, Santos CLS et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 290, 309-319 (2002).
22. Marianneau P, Georges-Courbot MC, Deubel V. Rarity of adverse effects after 17D yellow fever vaccination. Lancet 358, 84-85 (2001).
23. Lang J, Zuckerman J, Clarke P et al. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am. J. Trop. Med. Hyg. 60, 1045-1050 (1999). Overviews the reports of vaccine-associated viscerotropic disease first described in 2001.
24. Monath TP, Nichols R, Archambault WT et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (Arilvax and YF-VAX) in a Phase III multicenter, double-blind clinical trial. Am. J. Trop. Med. Hyg. 66, 533-541 (2002). Reports the most recent clinical trial with Arilvax.
25. Nathan N, Barry M, Van Herp M, Zeller H. Shortage of vaccines during a yellow fever outbreak in Guinea. Lancet 358, 2129-2130 (2001). Demonstrates the important point regarding the limited supplies of yellow fever vaccine for use in controlling epidemics.
26. Werfel U, Popp W. Effects of yellow fever vaccination. Lancet 358, 1909 (2001).
27. Troillet N, Laurencet F. Effects of yellow fever vaccination. Lancet 358, 1908-1909 (2001).
28. Adhiyaman V, Oke A, Cefai C. Effects of yellow fever vaccination. Lancet 358, 1907-1908 (2001).
29. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, Arilvax. Vaccine 22, 2103-2105 (2004). Describes serious adverse events for Arilvax from 1993-2001.
30. Monath TP, McCarthy K, Bedford P et al. Clinical proof principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20, 1004-1018 (2002). Describes the ChimeriVax platform and its potential applications.